JP2010530432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530432A5 JP2010530432A5 JP2010513267A JP2010513267A JP2010530432A5 JP 2010530432 A5 JP2010530432 A5 JP 2010530432A5 JP 2010513267 A JP2010513267 A JP 2010513267A JP 2010513267 A JP2010513267 A JP 2010513267A JP 2010530432 A5 JP2010530432 A5 JP 2010530432A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- phenyl
- fluorophenyl
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 difluorophenylmethylthiazolyl Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 102000011990 Sirtuin Human genes 0.000 claims 4
- 108050002485 Sirtuin Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000003381 solubilizing effect Effects 0.000 claims 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 108091005770 SIRT3 Proteins 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 102000056482 human SIRT1 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- LVDUUIXBZXBALU-UHFFFAOYSA-N CC(C)NCc1cnc2[s]c(-c(cccc3)c3NC(c3cc(-c4ccccc4)cnc3)=O)nc2c1 Chemical compound CC(C)NCc1cnc2[s]c(-c(cccc3)c3NC(c3cc(-c4ccccc4)cnc3)=O)nc2c1 LVDUUIXBZXBALU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663607P | 2007-06-20 | 2007-06-20 | |
| US60/936,636 | 2007-06-20 | ||
| PCT/US2008/007776 WO2008156869A2 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating thiazolopyridine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530432A JP2010530432A (ja) | 2010-09-09 |
| JP2010530432A5 true JP2010530432A5 (enExample) | 2011-08-04 |
| JP5498940B2 JP5498940B2 (ja) | 2014-05-21 |
Family
ID=39798234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513267A Expired - Fee Related JP5498940B2 (ja) | 2007-06-20 | 2008-06-20 | サーチュイン調節性チアゾロピリジン化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7893086B2 (enExample) |
| EP (1) | EP2170905A2 (enExample) |
| JP (1) | JP5498940B2 (enExample) |
| KR (1) | KR20100051048A (enExample) |
| CN (2) | CN101801981A (enExample) |
| AR (1) | AR067107A1 (enExample) |
| AU (1) | AU2008266749C1 (enExample) |
| BR (1) | BRPI0813651A2 (enExample) |
| CA (1) | CA2691733A1 (enExample) |
| CL (1) | CL2008001822A1 (enExample) |
| CO (1) | CO6251248A2 (enExample) |
| CR (1) | CR11232A (enExample) |
| DO (1) | DOP2009000284A (enExample) |
| EA (1) | EA018922B1 (enExample) |
| IL (1) | IL202730A0 (enExample) |
| MA (1) | MA31506B1 (enExample) |
| MX (1) | MX2009013977A (enExample) |
| NZ (1) | NZ581990A (enExample) |
| PE (1) | PE20090694A1 (enExample) |
| TW (1) | TW200916472A (enExample) |
| UY (1) | UY31169A1 (enExample) |
| WO (1) | WO2008156869A2 (enExample) |
| ZA (1) | ZA200908883B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| US8293747B2 (en) * | 2007-07-19 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| CN101910184A (zh) * | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
| JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
| AU2009266889B2 (en) | 2008-07-03 | 2013-05-02 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
| CN102227420B (zh) | 2008-09-29 | 2015-06-24 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物 |
| WO2010077642A1 (en) | 2008-12-08 | 2010-07-08 | Northwestern University | Method of modulating hsf-1 |
| JP5628828B2 (ja) | 2008-12-19 | 2014-11-19 | サートリス ファーマシューティカルズ， インコーポレイテッド | チアゾロピリジンサーチュイン調節化合物 |
| US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| CA2794018C (en) * | 2010-03-24 | 2016-05-10 | Medical University Of South Carolina | Compositions and methods for the treatment of degenerative diseases |
| WO2011130595A2 (en) * | 2010-04-15 | 2011-10-20 | Sirtris Pharmaceuticals, Inc. | Sirtuin activators and activation assays |
| RU2693462C2 (ru) * | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
| TW201223956A (en) | 2010-08-13 | 2012-06-16 | Solvay | Light emitting materials for electronics |
| EP2423214A1 (en) | 2010-08-13 | 2012-02-29 | Solvay SA | Light emitting materials for Electronics |
| KR20120047341A (ko) * | 2010-10-21 | 2012-05-14 | 경상대학교산학협력단 | 니코틴아미드를 유효성분으로 포함하는 알킬화 약물-유도성 신경퇴행의 예방 또는 치료용 조성물 |
| EP2670404B1 (en) | 2011-02-02 | 2018-08-29 | The Trustees of Princeton University | Sirtuin modulators as virus production modulators |
| KR101329524B1 (ko) | 2011-05-23 | 2013-11-13 | 연세대학교 산학협력단 | 미분화 전능성 줄기세포의 선택적 세포사멸 방법 |
| PH12014500198A1 (en) | 2011-07-15 | 2017-02-10 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways |
| WO2013036720A1 (en) | 2011-09-07 | 2013-03-14 | Cornell University | Methods for treatment of cancer by targeting sirt5 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| JP6469015B2 (ja) | 2012-11-13 | 2019-02-13 | ニューサート サイエンシーズ， インコーポレイテッド | エネルギー代謝を増大させるための組成物および方法 |
| US9585876B2 (en) | 2013-03-15 | 2017-03-07 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| JP2017506651A (ja) | 2014-02-27 | 2017-03-09 | ニューサート サイエンシーズ， インコーポレイテッド | 脂肪肝の低減または予防のための組成物および方法 |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015186068A1 (en) | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN107496410A (zh) * | 2017-09-21 | 2017-12-22 | 上海华堇生物技术有限责任公司 | 洋槐黄素的药物用途 |
| JP2021501198A (ja) * | 2017-10-27 | 2021-01-14 | トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー | フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
| WO2024005905A2 (en) * | 2022-04-29 | 2024-01-04 | The Regents Of The University Of Michigan | Small molecule sirtuin inhibitors and uses thereof |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164603A (en) | 1965-01-05 | xnhcox | ||
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| FR1439129A (fr) | 1965-04-02 | 1966-05-20 | Chimetron | Nouveaux sulfonylbenzimidazoles |
| FR1476529A (fr) | 1965-04-24 | 1967-04-14 | Chimetron Sarl | Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants |
| FR1450625A (fr) | 1965-06-18 | 1966-06-24 | Chimetron Sarl | Sulfonamidothiazolyl-2 benzimidazoles |
| US3503929A (en) | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
| US3517007A (en) | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| US3928228A (en) | 1969-04-28 | 1975-12-23 | Sterling Drug Inc | 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby |
| US3712888A (en) | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
| CA1006165A (en) | 1971-04-06 | 1977-03-01 | Eastman Kodak Company | Ballasted color photographic couplers |
| AR208500A1 (es) | 1972-06-14 | 1977-02-15 | Merck & Co Inc | Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas |
| US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| PL96241B1 (pl) | 1975-06-30 | 1977-12-31 | Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli | |
| JPS6040016B2 (ja) | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
| US4471040A (en) | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| DE3807084A1 (de) | 1988-03-04 | 1989-09-14 | Knoll Ag | Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung |
| JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH04191736A (ja) | 1990-11-27 | 1992-07-10 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| JPH06247969A (ja) | 1992-12-28 | 1994-09-06 | Takeda Chem Ind Ltd | 縮合複素環化合物及びそれを含む農園芸用殺虫剤 |
| ES2172585T3 (es) | 1994-05-31 | 2002-10-01 | Mitsui Chemicals Inc | Derivado de benzoimidazol. |
| US5821258A (en) | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
| AUPN449295A0 (en) | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5808087A (en) | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
| IL136911A0 (en) | 1997-12-31 | 2001-06-14 | Univ Rutgers | Heterocyclic topoisomerase poisons |
| WO1999051605A1 (en) | 1998-03-31 | 1999-10-14 | Shionogi & Co., Ltd. | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR |
| ID29244A (id) | 1998-08-20 | 2001-08-16 | Agouron Pharma | ZAT-ZAT GnRH NON-PEPTIDA, METODE-METODE DAN ZAT-ZAT ANTARA PEMBUATANNYA |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
| PT1194425E (pt) | 1999-06-23 | 2005-10-31 | Aventis Pharma Gmbh | Benzimidazoles substituidos |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| AU2001258784A1 (en) | 2000-05-22 | 2001-12-03 | Takeda Chemical Industries Ltd. | Tyrosine phosphatase inhibitors |
| AU2001259707A1 (en) | 2000-06-14 | 2001-12-24 | Warner Lambert Company | 6,5-fused bicyclic heterocycles |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| JP2002161084A (ja) | 2000-11-28 | 2002-06-04 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
| US20040010033A1 (en) | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
| WO2002066454A1 (fr) | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| CN1514833A (zh) | 2001-03-28 | 2004-07-21 | ����˹�ж�-����˹˹������˾ | 新型酪氨酸激酶抑制剂 |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US6716866B2 (en) | 2001-06-13 | 2004-04-06 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003011219A2 (en) | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2004043335A2 (en) | 2001-09-13 | 2004-05-27 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| AU2002349705A1 (en) | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| AU2003244463A1 (en) | 2002-02-05 | 2003-09-02 | Yamanouchi Pharmaceutical Co., Ltd. | 2,4,6-triamino-1,3,5-triazine derivative |
| KR20040084896A (ko) | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
| ATE432261T1 (de) | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
| NZ535603A (en) | 2002-03-20 | 2007-10-26 | Metabolex Inc | Substituted phenylacetic acids |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| JP4224979B2 (ja) | 2002-04-09 | 2009-02-18 | 大正製薬株式会社 | インターロイキン１２抑制剤 |
| JP4239463B2 (ja) | 2002-04-09 | 2009-03-18 | 大正製薬株式会社 | ３−トリフルオロメチルアニリド誘導体 |
| KR20040099449A (ko) | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
| JP2003313176A (ja) | 2002-04-24 | 2003-11-06 | Sankyo Co Ltd | アミノアゾール誘導体 |
| JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| DE50312261D1 (de) | 2002-07-12 | 2010-02-04 | Sanofi Aventis Deutschland | Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7847101B2 (en) | 2002-07-24 | 2010-12-07 | Valocor Therapeutics, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| EP1551809A1 (en) | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| WO2004033666A2 (en) | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
| US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| AU2003286757B2 (en) | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| AU2003302497A1 (en) | 2002-11-27 | 2004-06-23 | Ph. D. Edward M. Eddy | Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
| DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
| JP2006516626A (ja) | 2003-01-28 | 2006-07-06 | スミスクライン ビーチャム コーポレーション | 化学的化合物 |
| CA2515215A1 (en) | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| JP2006519833A (ja) | 2003-03-11 | 2006-08-31 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子（ｔｇｆ）阻害剤としてのピラジン化合物 |
| JP2006520794A (ja) | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| GB2405793A (en) | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
| AU2004271721A1 (en) | 2003-09-12 | 2005-03-24 | 4 Aza Bioscience Nv | Pteridine derivatives for the treatment of septic shock and TNF-alpha-related diseases. |
| MXPA06002943A (es) | 2003-09-19 | 2006-05-31 | Hoffmann La Roche | Derivados de tiazolopiridina como ligandos del receptor de adenosina. |
| JP4795634B2 (ja) | 2003-10-31 | 2011-10-19 | 出光興産株式会社 | 有機薄膜トランジスタ |
| JP2005162855A (ja) | 2003-12-02 | 2005-06-23 | Konica Minolta Holdings Inc | 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法 |
| CA2553704C (en) | 2004-02-11 | 2011-04-19 | Basilea Pharmaceutica Ag | Substituted benzimidazoles and their use for inducing apoptosis |
| WO2005100342A1 (en) * | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
| DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| ES2401138T3 (es) | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| CA2587489C (en) | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| JP4635633B2 (ja) | 2005-02-04 | 2011-02-23 | 横浜ゴム株式会社 | 空気入りタイヤおよびその製造方法 |
| EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| CA2618370A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7935957B2 (en) * | 2005-08-12 | 2011-05-03 | Semiconductor Energy Laboratory Co., Ltd. | Memory device and a semiconductor device |
| JP4191736B2 (ja) | 2006-01-11 | 2008-12-03 | 日本電信電話株式会社 | 電界通信システム |
| ES2431163T3 (es) | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 CL CL2008001822A patent/CL2008001822A1/es unknown
- 2008-06-19 TW TW097122810A patent/TW200916472A/zh unknown
- 2008-06-20 CA CA002691733A patent/CA2691733A1/en not_active Abandoned
- 2008-06-20 AR ARP080102663A patent/AR067107A1/es not_active Application Discontinuation
- 2008-06-20 MX MX2009013977A patent/MX2009013977A/es active IP Right Grant
- 2008-06-20 CN CN200880103654A patent/CN101801981A/zh active Pending
- 2008-06-20 WO PCT/US2008/007776 patent/WO2008156869A2/en not_active Ceased
- 2008-06-20 AU AU2008266749A patent/AU2008266749C1/en not_active Ceased
- 2008-06-20 US US12/214,805 patent/US7893086B2/en not_active Expired - Fee Related
- 2008-06-20 KR KR1020107000400A patent/KR20100051048A/ko not_active Ceased
- 2008-06-20 JP JP2010513267A patent/JP5498940B2/ja not_active Expired - Fee Related
- 2008-06-20 BR BRPI0813651-3A2A patent/BRPI0813651A2/pt not_active IP Right Cessation
- 2008-06-20 CN CN201310744228.7A patent/CN103833775A/zh active Pending
- 2008-06-20 NZ NZ581990A patent/NZ581990A/en not_active IP Right Cessation
- 2008-06-20 EP EP08768700A patent/EP2170905A2/en not_active Withdrawn
- 2008-06-20 EA EA201070035A patent/EA018922B1/ru not_active IP Right Cessation
- 2008-06-20 PE PE2008001058A patent/PE20090694A1/es not_active Application Discontinuation
- 2008-06-20 UY UY31169A patent/UY31169A1/es not_active Application Discontinuation
-
2009
- 2009-12-11 DO DO2009000284A patent/DOP2009000284A/es unknown
- 2009-12-14 IL IL202730A patent/IL202730A0/en unknown
- 2009-12-14 ZA ZA200908883A patent/ZA200908883B/xx unknown
-
2010
- 2010-01-07 MA MA32482A patent/MA31506B1/fr unknown
- 2010-01-08 CO CO10001887A patent/CO6251248A2/es not_active Application Discontinuation
- 2010-01-20 CR CR11232A patent/CR11232A/es not_active Application Discontinuation
-
2011
- 2011-01-24 US US13/012,775 patent/US8268862B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530432A5 (enExample) | ||
| JP2010530431A5 (enExample) | ||
| JP7262599B2 (ja) | タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 | |
| TWI280127B (en) | Remedies for neurodegenerative diseases | |
| Côté et al. | Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses | |
| AU2018275277B2 (en) | Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof | |
| AU2012208388C1 (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | |
| NZ594122A (en) | 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| US5721277A (en) | Compounds and methods for inhibiting hyper-proliferative cell growth | |
| CA2697077A1 (en) | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | |
| US20110112110A1 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| WO2020052627A1 (zh) | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 | |
| Wrobleski et al. | Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions | |
| CN101584691A (zh) | 影响葡糖激酶的化合物 | |
| TW200817350A (en) | Biaryloxymethylarenecarboxylic acids | |
| SI9520081A (en) | Use of thiazoles and thiadiazoles compounds as d3 dopamine receptor ligands. | |
| TW200410675A (en) | An NF-κB activation inhibitor | |
| KR101572280B1 (ko) | 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제 | |
| EP2272509A1 (en) | New Uses of metabotropic glutamate receptors | |
| CN110885332B (zh) | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 | |
| KR20110027817A (ko) | Ｍｇｌｕｒ 조절제를 포함하는 파킨슨병 치료용 조합물 | |
| TR201908676T4 (tr) | Mesane idrar yolu hastalıklarının önlenmesinde veya tedavisinde kullanıma yönelik 2-asilaminotiyazol türevi. | |
| RU2512547C2 (ru) | Содержащее конденсированную кольцевую структуру производное и его применение в медицине | |
| Lu et al. | Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant |